Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

WAVE LIFE SCIENCES LTD.

(WVE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/17/2021 09/20/2021 09/21/2021 09/22/2021 09/23/2021 Date
5.68(c) 5.6(c) 5.68(c) 5.85(c) 6.08(c) Last
832 414 271 644 126 278 120 157 153 428 Volume
+3.27% -1.41% +1.43% +2.99% +3.93% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 32,4 M - -
Net income 2021 -145 M - -
Net cash position 2021 94,3 M - -
P/E ratio 2021 -2,16x
Yield 2021 -
Sales 2022 44,8 M - -
Net income 2022 -140 M - -
Net cash position 2022 131 M - -
P/E ratio 2022 -2,74x
Yield 2022 -
Capitalization 309 M 309 M -
EV / Sales 2021 6,61x
EV / Sales 2022 3,97x
Nbr of Employees 219
Free-Float 95,3%
More Financials
Company
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the... 
Sector
Biotechnology & Medical Research
Calendar
09/23 | 08:30amPresentation
More about the company
Ratings of Wave Life Sciences Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about WAVE LIFE SCIENCES LTD.
09/22Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
GL
09/10WAVE LIFE SCIENCES LTD. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
09/09WAVE LIFE SCIENCES : Begins Dosing in Phase 1b/2a Trial of Potential Drug for Huntington's..
MT
09/09Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Tri..
GL
09/09Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Tri..
CI
09/08Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs ..
GL
09/07Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conf..
GL
09/07Wave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements Du..
GL
08/16WAVE LIFE SCIENCES LTD. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
08/16WAVE LIFE SCIENCES : Submission of Matters to a Vote of Security Holders (Form 8-K)
PU
08/12WAVE LIFE SCIENCES : Mizuho Securities Lifts Price Target on WAVE Life Sciences to $13 Fro..
MT
08/05WAVE LIFE SCIENCES : Q2 Earnings Snapshot
AQ
08/05WAVE LIFE SCIENCES : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08/05WAVE LIFE SCIENCES LTD. : Results of Operations and Financial Condition, Financial Stateme..
AQ
08/05WAVE LIFE SCIENCES : Earnings Flash (WVE) WAVE LIFE SCIENCES USA Posts Q2 Revenue $2.78M
MT
More news
News in other languages on WAVE LIFE SCIENCES LTD.
09/09WAVE Life Sciences commence le dosage d'un essai de phase 1b/2a sur un médicament poten..
07/23DGAP-NEWS : Biotechbranche mit solidem 2. Quartal -2-
04/23DGAP-NEWS : BB BIOTECH AG: Erfolgreiche -2-
More news
Analyst Recommendations on WAVE LIFE SCIENCES LTD.
More recommendations
Chart WAVE LIFE SCIENCES LTD.
Duration : Period :
Wave Life Sciences Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WAVE LIFE SCIENCES LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 6,08 $
Average target price 9,86 $
Spread / Average Target 62,1%
EPS Revisions
Managers and Directors
Paul B. Bolno President, Chief Executive Officer & Director
Kyle Moran Chief Financial & Accounting Officer
Christian O. Henry Chairman
Chandra Vargeese Chief Technology Officer
Michael Panzara Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
WAVE LIFE SCIENCES LTD.-22.74%309
GILEAD SCIENCES, INC.23.05%89 497
BIONTECH SE333.01%81 938
WUXI APPTEC CO., LTD.33.88%69 841
REGENERON PHARMACEUTICALS33.82%67 273
VERTEX PHARMACEUTICALS-21.68%47 805